Evaluation of Dose Changes to Target and Critical Structures from Rotational Setup Errors (RSE) in Prostate Cancer Patients Treated with Proton Therapy

2008 ◽  
Vol 72 (1) ◽  
pp. S321
Author(s):  
S.V. Sejpal ◽  
R.A. Amos ◽  
J.B. Bluett ◽  
L.B. Levy ◽  
R.J. Kudchadker ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Proton Therapy ◽  
Setup Errors

Safety of proton therapy treatment for prostate cancer patients with unilateral hip replacements.

2011 ◽  
Vol 29 (7_suppl) ◽  
pp. 100-100
Author(s):  
R. C. Nichols ◽  
B. S. Hoppe ◽  
M. W. Ho ◽  
H. Martinez ◽  
R. H. Henderson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Proton Therapy ◽  
Hip Replacement ◽  
Rectal Balloon ◽  
Increased Risk ◽  
Hip Replacements ◽  
Skeletal Complications ◽  
Grade 3 ◽  
Experienced Grade

100 Background: Determine the feasibility of proton therapy for prostate cancer patients who have undergone unilateral hip replacement. Methods: From January, 2007 to March, 2008 5 patients with localized (4) or locally recurrent (1) prostate cancer and previous unilateral hip replacement underwent hip avoiding proton therapy. The median target dose was 78 Cobalt Gray Equivalent (Range 74CGE to 82CGE). All patients were treated in the supine position without a rectal balloon. Median maximum (1cc) dose to the normal femoral head was 51.47CGE (Range 43.82CGE to 64.50CGE). All patients signed informed consent and were registered to either the IRB approved UFPTI PR01, PR02 or Outcome Tracking (OTP) Protocols. Results: With a median follow up of 28 (range 15 to 39) months, no patient experienced grade 2 or higher late rectal toxicity. No patient experienced grade 3 or higher late urinary toxicity. Two patients experienced grade 2 urinary toxicity by virtue of having been placed on medication (tamsulosin) for urinary obstructive symptoms. No patient has reported hip fracture, hip pain or other skeletal event in the normal hip. Conclusions: Our experience suggests that patients with unilateral hip replacements can be treated with hip avoiding proton therapy without an increased risk of urinary, rectal or skeletal complications. No significant financial relationships to disclose.

scholarly journals Initial clinical outcomes for prostate cancer patients undergoing adjuvant or salvage proton therapy after radical prostatectomy

2020 ◽  
Vol 59 (10) ◽  
pp. 1235-1239 ◽  
Author(s):  
Curtiland Deville ◽  
Wei-Ting Hwang ◽  
Andrew R. Barsky ◽  
Stefan Both ◽  
John P. Christodouleas ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Cancer Patients ◽  
Clinical Outcomes ◽  
Proton Therapy

Clinical Assessment of Proton Therapy of Prostate Cancer Patients With Auto Activation PET/CT

2012 ◽  
Vol 84 (3) ◽  
pp. S367-S368
Author(s):  
S. Takamatsu ◽  
M. Kawamura ◽  
H. Tamamura ◽  
M. Sasaki ◽  
Y. Maeda ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Proton Therapy ◽  
Clinical Assessment ◽  
Pet Ct
Sign in / Sign up

Export Citation Format

Share Document